右美托咪定对肿瘤作用的研究进展  

Research progress of dexmedetomidine on cancer

作　　者：刘晓田 郑永锋[1] 马晓冬[1] 谢云斌 程应湘 邵东华[1] Xiao-tian Liu;Yong-feng Zheng;Xiao-dong Ma;Yun-bin Xie;Ying-xiang Cheng;Dong-hua Shao(Department of Anesthesiology,Affiliated People’s Hospital of Jiangsu University,Zhenjiang,Jiangsu 212002,China)

机构地区：[1]江苏大学附属人民医院麻醉科,江苏镇江212002

出　　处：《中国现代医学杂志》2020年第15期50-54,共5页China Journal of Modern Medicine

摘　　要：手术是目前治疗多数实体肿瘤的首选方法,围手术期麻醉药的使用对肿瘤发展及预后产生极大的影响。右美托咪定是目前临床常用的麻醉药物之一,广泛应用于全身麻醉和区域阻滞。研究发现,右美托咪定在体内外可促进乳腺癌、肺癌和胃肠道肿瘤的进展,也有数据提示右美托咪定可抑制卵巢癌、骨肉瘤的生长。探究右美托咪定对肿瘤的作用可以指导临床用药,规避临床风险。该文对右美托咪定对肿瘤的影响及机制作一综述。Surgery is currently the preferred treatment for most solid tumors.Many factors in the perioperative period,such as the use of anesthetics,would have a great impact on the development and prognosis of tumor.Dexmedetomidine is one of the most common anesthetics used in clinical general anesthesia and regional block.Studies found that dexmedetomidine might promote the progression of breast,lung and gastrointestinal cancer in vitro and in vivo,yet data also suggested that dexmedetomidine could inhibit the growth of ovarian cancer and osteosarcoma.Exploring the effect of dexmedetomidine on cancer can better guide clinical medications and circumvent risks.This review would briefly introduce the clinical pharmacology of dexmedetomidine and summarize the recent trends concerning the effect of dexmedetomidine on tumor.

关 键 词：右美托咪定 肿瘤 α2肾上腺素受体 免疫 

分 类 号：R614[医药卫生—麻醉学]